Alpha 2.0
Login Register
» Articles » PMID: 37047470

Effects of Mineralocorticoid Receptor Blockade and Statins on Kidney Injury Marker 1 (KIM-1) in Female Rats Receiving L-NAME and Angiotensin II

Overview
Journal Int J Mol Sci
Publisher MDPI
Specialties Biochemistry
Chemistry
Molecular Biology
Date 2023 Apr 13
PMID 37047470
Authors
Jiayan Huang
Ezgi Caliskan Guzelce
Shadi K Gholami
Kara L Gawelek
Richard N Mitchell
Luminita H Pojoga
Jose R Romero
Gordon H Williams
Gail K Adler
Affiliations
Soon will be listed here.
Abstract

Kidney injury molecule-1 (KIM-1) is a biomarker of renal injury and a predictor of cardiovascular disease. Aldosterone, via activation of the mineralocorticoid receptor, is linked to cardiac and renal injury. However, the impact of mineralocorticoid receptor activation and blockade on KIM-1 is uncertain. We investigated whether renal KIM-1 is increased in a cardiorenal injury model induced by L-NAME/ANG II, and whether mineralocorticoid receptor blockade prevents the increase in KIM-1. Since statin use is associated with lower aldosterone, we also investigated whether administering eiSther a lipophilic statin (simvastatin) or a hydrophilic statin (pravastatin) prevents the increase in renal KIM-1. Female Wistar rats (8-10 week old), consuming a high salt diet (1.6% Na+), were randomized to the following conditions for 14 days: control; L-NAME (0.2 mg/mL in drinking water)/ANG II (225 ug/kg/day on days 12-14); L-NAME/ANG II + eplerenone (100 mg/kg/day p.o.); L-NAME/ANG II + pravastatin (20 mg/kg/day p.o.); L-NAME/ANG II + simvastatin (20 mg/kg/day p.o.). Groups treated with L-NAME/ANG II had significantly higher blood pressure, plasma and urine aldosterone, cardiac injury/stroke composite score, and renal KIM-1 than the control group. Both eplerenone and simvastatin reduced 24-h urinary KIM-1 ( = 0.0046, = 0.031, respectively) and renal KIM-1 immunostaining ( = 0.004, = 0.037, respectively). Eplerenone also reduced renal KIM-1 mRNA expression ( = 0.012) and cardiac injury/stroke composite score ( = 0.04). Pravastatin did not affect these damage markers. The 24-h urinary KIM-1, renal KIM-1 immunostaining, and renal KIM-1 mRNA expression correlated with cardiac injury/stroke composite score ( < 0.0001, Spearman ranked correlation = 0.69, 0.66, 0.59, respectively). In conclusion, L-NAME/ANG II increases renal KIM-1 and both eplerenone and simvastatin blunt this increase in renal KIM-1.

References
1.
Pojoga L, Romero J, Yao T, Loutraris P, Ricchiuti V, Coutinho P . Caveolin-1 ablation reduces the adverse cardiovascular effects of N-omega-nitro-L-arginine methyl ester and angiotensin II. Endocrinology. 2010; 151(3):1236-46. PMC: 2840694. DOI: 10.1210/en.2009-0514. View
2.
Zhang Y, Rong S, Feng Y, Zhao L, Hong J, Wang R . Simvastatin attenuates renal ischemia/reperfusion injury from oxidative stress via targeting Nrf2/HO-1 pathway. Exp Ther Med. 2017; 14(5):4460-4466. PMC: 5647698. DOI: 10.3892/etm.2017.5023. View
3.
van Timmeren M, Vaidya V, van Ree R, Oterdoom L, de Vries A, Gans R . High urinary excretion of kidney injury molecule-1 is an independent predictor of graft loss in renal transplant recipients. Transplantation. 2008; 84(12):1625-30. PMC: 2745062. DOI: 10.1097/01.tp.0000295982.78039.ef. View
4.
Gohda T, Kamei N, Koshida T, Kubota M, Tanaka K, Yamashita Y . Circulating kidney injury molecule-1 as a biomarker of renal parameters in diabetic kidney disease. J Diabetes Investig. 2019; 11(2):435-440. PMC: 7078097. DOI: 10.1111/jdi.13139. View
5.
de Zeeuw D, Anzalone D, Cain V, Cressman M, Lambers Heerspink H, Molitoris B . Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes Endocrinol. 2015; 3(3):181-90. DOI: 10.1016/S2213-8587(14)70246-3. View